# Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation

Study · id `cardio:ct-nct01873352` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01873352](<https://clinicaltrials.gov/study/NCT01873352>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01873352

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: High blood pressure; Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 302 participants.

## Technical summary

Registry record NCT01873352. Randomized; single masking; primary purpose treatment. Start 2013-06-20 (actual); primary completion 2019-03-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 302 participants (enrolled count; ClinicalTrials.gov record NCT01873352, source copy `cardio:ctgov-nct01873352-2019-09-04`, retrieved 2026-10-26)
- Started: 2013-06-20 (actual) (ClinicalTrials.gov record NCT01873352, source copy `cardio:ctgov-nct01873352-2019-09-04`, retrieved 2026-10-26)
- Primary completion: 2019-03-01 (actual) (ClinicalTrials.gov record NCT01873352, source copy `cardio:ctgov-nct01873352-2019-09-04`, retrieved 2026-10-26)
- Completion: 2019-03-01 (actual) (ClinicalTrials.gov record NCT01873352, source copy `cardio:ctgov-nct01873352-2019-09-04`, retrieved 2026-10-26)
- Countries: United States; Russia (ClinicalTrials.gov record NCT01873352, source copy `cardio:ctgov-nct01873352-2019-09-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01873352-2019-09-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation
- Acronym: ERADICATE--AF
- Condition: Atrial Fibrillation
- Condition: Hypertension
- Intervention (Procedure): catheter ablation
- Intervention (Procedure): renal sympathetic denervation
- Lead sponsor: Meshalkin Research Institute of Pathology of Circulation
- Lead sponsor class: NETWORK

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Meshalkin Research Institute of Pathology of Circulation (`cardio:org-meshalkin-research-institute-of-pathology-of-circulation`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial (`cardio:pubmed-31961420`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f9daec46891a46279500d2e4c62ed33b577968723a6cf8d5a884c2eac9c17f91
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
